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Introduction
Schizophrenia is a highly debilitating global illness which affects at least 28 million people worldwide [1] . Atypical antipsychotics have been considered the first option of treatment in schizophrenic disorders, due to their superior effect on psychotic symptoms coupled with a lower risk of extrapyramidal symptoms (EPS) such as tardive dyskinesia [2] . Olanzapine (OLZ)
is among other atypical antipsychotics an effective antipsyhotic medication. However, its utility has so far been currently limited to most patients due to its high risk of developing metabolic disturbances such as insulin-resistance (IR), dyslipidemia and obesity thus predisposing patients to metabolic syndrome (MetS) [34] . It could increase risks of cardiovascular diseases (CVD), which account for most mortality in schizophrenia patients [56] .
Therefore, a method of predicting and preventing metabolic abnormalities before OLZ treatment is urgently needed. As OLZ could lead to increased risk of diabetes mellitus and dyslipidemia thus CVD risks, considerable attention has been given to this issue in recent years [78] . Previous studies have shown OLZ has an adverse impact on glycolipid metabolism and explored its underlying mechanisms. Many hypotheses about OLZ-induced metabolic disturbances have been raised, including many different relative receptors such as histamine H1, serotonin 5-HT2C, 5-HT2A, dopamine D2, muscarinic M2, M3, and adrenergic receptors [9] , but mechanism by which OLZ causes metabolic problems has not been adequately explained, so prediction and prevention still remain unattainable.
Nowadays, metabolic disorders have been regarded as mild inflammatory diseases, in which cytokines play key roles in regulating inflammatory responses. Many cytokines have been speculated to be involved in metabolic diseases and CVD like IR, diabetes mellitus (DM), hypertension (HTN) and coronary artery disease (CAD) [10] . For example, increased amounts of various cytokines like tumor necrosis factor-α (TNF-α) expressed in adipose tissue are found to be associated with obesity and infiltration of multiple immune cells including monocytes/macrophages B and T lymphocytes [11] . TNF-α also inhibits the differentiation of adipose cells [11] . Recent studies indicate that interleukin (IL)-1β participates in β-cell death and dysfunction in type 1 and type 2 DM (T2DM) [12] . In vivo studies of T2DM patients and animal models have shown evidence of raised IL-1β expression in the circulation, the pancreas, and in insulin target tissues [12] . IL-1β may also disrupt glucose-stimulated insulin secretion in isolated islets [13] . Moreover, improved glycemic control was observed in animals and humans after IL-1β antibody (IL-1βAb) treatment [14] . Likewise, IL-1 receptor antagonist (IL-1ra), IL-8 , macrophage chemo-attractant protein (MCP)-1, interferon-γ (IFN-γ) and vascular endothelial growth factor (VEGF) were elevated in the blood of obese patients [15] [16] [17] [18] .
Increased IL-1ra and IL-8 were also associated with IR [1719] . As a growth factor, leptin not only regulates the proliferation of naive and memory T cells [20] , but manipulates satiety by inhibiting appetite [21] . It was postulated that leptin resistance occurred in obese people so that satiety signals were disrupted, leading to obesity. VEGF-B gene deletion in models of
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A C C E P T E D M A N U S C R I P T obesity mice showed improved insulin sensitivity [22] .
Psychosis, including schizophrenia, had been found to be associated with elevated risk in metabolic disorders such as MetS, DM and CVD. Mitchell et al. [23] found a higher prevalence of MetS and metabolic disturbances which contributed to cardiovascular risk in patients with schizophrenia in a systematic review and meta-analysis. Zhang et al. [24] and Enez Darcin A et al. [25] also found a greater severity of glucolipid disturbance in first-episode drug-naïve schizophrenia and drug-free schizophrenia
In addition, many cytokines have been found increased in psychosis than health control (HC).A recent meta-analysis by Goldsmith et al. [26] showed Levels of IFN-γ, IL-1ra, IL-1β, soluble IL-2 receptor (sIL-2 R),IL-6, IL-8, IL-10, IL-12, transforming growth factor-β(TGF-β) and TNF-α were significantly increased in first-episode psychosis (FEP) compared with controls (P<0.01), whereas the levels of IL-4 were significantly decreased (P<0.01). The increase in pro-inflammatory factors and lower anti-inflammatory factor indicated a mild inflammatory state in schizophrenia patients, which might play a role in adverse metabolic effect and further genesis of CVD.
Although cytokines have a strong relationship with schizophrenia and metabolic disorders, abnormal baseline IL-6 (IL-6>5 pg/mL) significantly predicted a greater increase in both total cholesterol and low-density lipoprotein (LDL) [27] . Another study by Tsuneyama et al. studied baseline body mass index (BMI) and plasma levels of leptin, adiponectin, and TNF-α in 31 outpatients who were unmedicated or treated with aripiprazole, risperidone, blonanserin, or perospirone monotherapy over the past 4 weeks. He also found that, after OLZ monotherapy, BMI change from baseline to endpoint (8 weeks) was negatively-correlated with baseline leptin levels in female outpatients (r = -0.514, P = 0.024), but not male patients [28] . Studies on cytokine predicting adverse metabolic effects induced by OLZ are still limited. And there is no single study focusing on Chinese Han population. Furthermore, only a few cytokines were examined in existing studies.
Based on these studies, we decided to prioritize examining the level of 7 cytokines, IFN-γ, IL-1ra, IL-1β, IL-8, TNF-α, MCP-1,and VEGF, in hospitalized schizophrenic patients. To attain a more comprehensive understanding of cytokines and adverse metabolic effects induced by olanzapine, we performed a prospective cohort study and a cross-sectional study to investigate metabolic profiles, cytokine levels at baseline and 4-week intervals in total 8 weeks, searching for biomarkers which might predict the metabolic disturbances induced by OLZ treatment. Here, we examine the hypothesis that higher levels of baseline serum cytokine indicate the higher risk of developing adverse metabolic effect after OLZ treatment
A C C E P T E D M A N U S C R I P T in schizophrenia patients searching for biomarkers that predict OLZ-induced adverse metabolic effects.
Subjects and Methods
Subjects
23 inpatients (male/female = 18/5) were recruited from Shanghai Mental Health Center (SMHC) in China from October 2016 to May 2017. All patients met the diagnostic criteria of schizophrenia, as defined in International Classification of Diseases, Tenth Edition (ICD-10) [29] .
Medical histories and psychiatric diagnoses were confirmed by examining patient medical records and conducting semi-structured psychiatric interviews. Additional inclusion criteria included: (1) age from 18 to 65 years old, Han Chinese; (2) untreated with any antipsychotic medications or other psychotropics except benzodiazepines (BZ) within 6 months prior to the study screening, including those who were never medicated with any antipsychotic treatment ( Table 1) . Exclusion criteria were: (1) The study was approved by the Ethics Committee of Shanghai Mental Health Center, China. Permission and informed consent were obtained from all subjects.
Procedure
All blood samples were collected after an overnight fast of at least 12 h between 06:00-07:00 a.m. Blood samples were drawn from all patients at admission and after periods of 4 weeks and 8 weeks of OLZ treatment. At the same time, blood was drawn for laboratory tests of metabolic parameters. Blood samples of healthy controls were also obtained at baseline in fasting state. Blood (5 ml) was sampled using anticoagulant-free tubes and kept for 1 h at 4 °C (for platelet activation) before serum was isolated (centrifugation at 3000 rpm
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for 20 min at 4 °C). The separated serum was stored at −80 °C until being analyzed for cytokines.
Patients were assessed for psychopathological symptoms by using the Positive and Negative
Syndrome Scale (PANSS) [30] , an instrument that evaluates the severity of positive, negative and general psychopathology using thirty items ranked on a scale from 1 (absent) to 7
(extremely severe) for each item. Medical histories, including antipsychotic use and medical morbidity, were gathered from patients' medical records. Demographic and glucolipid metabolic data were obtained from interviews, laboratory results, and medical records.
Weight (kg) and height (m) were measured, and BMI was calculated as well.
Blood collection and clinical measurements
Glycolipid metabolic parameters and BMI were studied in this study. The levels of biochemical analysis, including triglycerides (TG), total cholesterol, LDL cholesterol, high-density lipoprotein (HDL) cholesterol, apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), lipoprotein a, fasting glucose, glycated hemoglobin A1c (HbA1c), and insulin levels were determined via standard laboratory methods using certified assays from the Shanghai Mental Health Center's Clinical Laboratory.
Cytokine and leptin assays
Multiplex kits for measuring cytokines were purchased from Bio-Rad (Human 
Statistical Analyses
Change of level was defined as the amount of subsequent alteration from baseline to endpoint (8 weeks). The normal distribution of data was tested using the Kolmogorov-Smirnov one-sample test. According to the results of the distribution, either the two-sample t test or Mann-Whitney U was performed in order to of the distribution test. To adjust for multiple testing, the Bonferroni correction was applied. We used repeated-measures analysis of variances (RM-ANOVA) to analyze clinical correlates and cytokines that were normally distributed both before and after OLZ treatment. As for those
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of non-normal distribution, Friedman two-way analysis was applied. Bonferroni corrections were applied to each comparison test to adjust for multiple testing. A Pearson correlation analysis or Spearman's rank correlation test was used to explore the correlation between cytokines and other parameters depending on whether the data was normally distributed.
Using baseline cytokine levels, along with age, sex and baseline variables significantly correlated with variable changes, stepwise multiple regression analysis was performed to evaluate the effects of independent variables with significant change following OLZ treatment (change of BMI, leptin, insulin, cholesterol, TG, LDL, and ApoB). Significance was defined at p value﹤0.05 (two-tailed).
All analyses were carried out using SPSS 20.0 for Windows (SPSS, Inc., Chicago, IL, USA).
Figures were made by using software GraphPad Prism 6.0. 
Results
Demographic and Clinical Characteristics of Participants.
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The comparison of cytokines between schizophrenia and HCs
IL-1ra, MCP-1 and VEGF levels were significantly higher in schizophrenia patients than HC (p=0.0001, p=0.003, p=0.014, Figure 1 ). Other cytokines were not significantly different between the two groups. Given the large number of comparisons (7) conducted in the correlational analyses, a Bonferroni correction (0.05/7) was applied with a significance level of p < 0.0071. Only IL-1ra and MCP-1 remain significantly higher. 
The change of metabolic parameters before and after OLZ treatment
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The mean dosage of OLZ at endpoint (8 weeks) was 17.8±6.2 mg. In the RM-ANOVA, there was a significant increase in BMI, leptin, fasting insulin, total cholesterol, TG, LDL, and ApoB (all P's< 0.01 except LDL, whose P = 0.034, Figure 2 ) following a 8-week of OLZ treatment, but not fasting glucose (P = 0.505), HbA1c (P = 0.133), HDL (P = 0.774), ApoA1 (P = 0.805), or lipoprotein a (P = 0.069) ( Table 2) . Changes of BMI, leptin, and glucose/lipid metabolism parameters insulin, cholesterol, TG, LDL, and ApoB were shown in Figure 2 . No significant difference was found in cytokines following 8-week OLZ treatment (data not shown). 
Baseline IL-1ra levels are associated with increase of cholesterol, LDL, ApoB and leptin levels
A Change in a parameter was defined as levels at end point minus baseline.
As shown in figure 3 , the mean change from baseline to endpoint (8 weeks) 
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Discussion
In our current study, we measured 7 cytokines and metabolic correlates before and after 8-weeks' OLZ treatment in schizophrenia patients. We found a significant elevation in BMI, fasting insulin, total cholesterol, TG, LDL, ApoB and leptin after 8 weeks of OLZ treatment, which confirmed that OLZ did induce metabolic side-effects after two-month treatment.
Numerous previous studies have shown significant increase in metabolic parameters , such as weight, BMI , leptin [33] , fasting insulin [3135] , total cholesterol, LDL and TG [27313335] , after OLZ treatment. The severe adverse metabolic effect of OLZ limited its clinical use, though OLZ among other atypical antipsychotics is an effective antipsychotic medication in acute psychosis [36] and most frequently prescribed in schizophrenic patients [37] . Therefore, identification of biomarkers that predict OLZ induced metabolic dysfunction might be helpful to guide clinicians in use of OLZ.
Interestingly, we found that only IL-1ra serum levels out of all 7 cytokines prior to OLZ treatment are significantly associated with increments of cholesterol, LDL, ApoB and leptin levels after 8-week of OLZ treatment, which indicated that the baseline serum levels of IL-1ra might be a biomarker for prediction of adverse metabolic effects induced by OLZ, although we did not find significant change in IL-1ra levels following 8 weeks of OLZ treatment compare to pre-treatment. In our present study, we also found significant higher serum levels of IL-Ira in schizophrenia patients before OLZ treatment compared with HC, which consisted with the finding of previous study that IL-1ra was increased in schizophrenia patients no matter acutely or chronically ill [26] . These suggested that IL-Ira might be associated the pathologic mechanisms of schizophrenia per se.
IL-1ra is an anti-inflammatory cytokine which inactivates IL-1 signaling by binding to the interleukin-1 receptor 1 (IL-1R1) and inhibiting IL-1 signaling [38] . Growing interest was present due to roles of IL-1ra in varieties of cardio-metabolic diseases, such as atherosclerosis [39] and T2DM [4041] . To our best knowledge, this is the first study showing that baseline serum IL-1ra level is a significant predictor of cholesterol-, LDL-, ApoB-and leptin increments following olanzapine treatment in schizophrenia population.
In the short time frame of our current study, patients had an elevated fasting lipid, leptin and insulin levels which serve as risk factors of suffering CVD after treated with olanzapine.
Therefore, an increase of baseline IL-1ra level may also predict CVD risks in schizophrenia patients on OLZ treatment. However, the mechanism by which cholesterol, LDL, ApoB and leptin changes are associated with blood IL-1ra levels prior to OLZ treatment is not clear.
Freitag et al. [42] studied a large number of people and found long-term IL-1 signal inhibition could lead to an increased risk of CVD partially through proatherogenic lipids increase, especially increased concentrations of LDL cholesterol and triglycerides. Another meta-analysis based on a total of 1855 CVD cases and 18,745 non-cases with follow-up times ranging from 5 to 16 years [42] found the pooled standardized hazard ratio (95% confidence interval) for incident CVD was 1.11 (1.06-1.17) Further studies are still needed to unveil the
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underlying mechanism of how IL-1ra influences the formation of CVD. Interestingly, in our study, baseline IL-1ra level also predicts the increased leptin level after OLZ treatment. In addition, we find a nearly correlation between baseline IL-1ra level and BMI in drug-free schizophrenia patients. Overall, our results suggest IL-1ra could become a novel biomarker predicting cholesterol-, LDL-, ApoB-and leptin increments or even CVD risk following OLZ treatment and serves to individualized therapy for schizophrenia patient.
Moreover in our present study, we also found the baseline level of another cytokine MCP-1 was significantly higher in schizophrenia patients compared with HC, which consisted with previous studies findings that increased MCP-1 levels in chronic schizophrenia compared with HC in their cross-sectional studies [43] [44] [45] . Likewise, it could be speculated that elevated levels of MCP-1 could serve as biomarkers as pathogenesis of schizophrenia.
Our study combined cross-sectional and follow-up methods. All patients recruited had not been medicated with any antipsychotics for at least 6 months prior to the study recruitment, so effect of antipsychotics on baseline levels of cytokines had been ruled out. Furthermore, multiple testing was applied to approve our statistical results. However, several limitations should be noted here. First, our sample size is small, which may lead to a potential bias.
Studies with larger sample are needed to confirm the results and identify vulnerable patient group. Second, the sample consists of a predominantly male population. The imbalance in the sex of our samples may lead to bias in the statistical analysis. Therefore we attempted to correct this effect in the statistical analysis. Fortunately, we did not find a sex effect. Third, our study found a predictive effect of IL-1ra in OLZ-induced adverse metabolic effect like cholesterol, LDL, ApoB and leptin increments, not of the other adverse metabolic effects of olanzapine treatment such as increments of BMI, insulin and TG. This might limit the value of IL-1ra as a predictive biomarker.
Conclusions
In summary, our findings showed that elevated levels of IL-1ra and MCP-1 might be biomarkers indicating the pathogenesis of schizophrenia, in which baseline IL-1ra may predict OLZ-induced holesterol-, LDL-, ApoB-and leptin elevations through association with higher lipid and leptin levels. The correlation between IL-1ra and increased levels of lipid and leptin in schizophrenia patients indicates that IL-1ra might participate in the development of adverse metabolic effects induced by OLZ, suggesting its promising prospective for further investigations as a molecular biomarker in schizophrenia. By measuring IL-1ra level at baseline, risk of adverse metabolic effect can be predicted, which serves to the determination of clinicians to switch to other antipsychotics other than OLZ. Furthermore, medications targeted on IL-1ra could reverse adverse side effect induced by OLZ in schizophrenia. Several studies had shown that patients with DM achieved improvement in IR after anakinra, an analog of IL-1ra, treatment [46] . Further studies are needed to examine the role of IL-1ra in adverse metabolic effects induced by other antipsychotics, especially in drug-free patients in different ethnicities.
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Highlights  We investigate if baseline cytokine in pathogenesis of schizophrenia and prediction for olanzapine (OLZ)-induced adverse metabolic effects.
 Some cytokines were higher in schizophrenia than health controls (HC).
 Higher IL-1ra was significantly correlated with higher hypercholesterolemia and hyperleptinemia following OLZ treatment.
 Some cytokines may be biomarkers indicating pathogenesis of schizophrenia and predicting subsequent higher possibility of hypercholesterolemia and hyperleptinemia following OLZ treatment.
